Jun 16, 2022 / 05:00PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Welcome, everyone, to our highlight, final presentation at the Goldman Sachs Healthcare Conference. We are so honored that J&J could come join us for this, apropos in so many ways, getting in the last word as they say. My name is Chris Shibutani. I'm a member of the research team. I cover pharmaceuticals and biotechnology.
Very quickly, I'll steal a moment from J&J and say thank you to so many folks who have pulled together this event. Just a tremendous amount of effort, a display of excellence across so many domains, within our conference planners, people who are too many to shout out, but obviously, this has been a tremendous effort.
Thank you also to our clients who joined together with us, took this bold step to be in person, I think, genuinely worthwhile, and we're seeing that manifest. I think this was an event that will continue to have opportunities, seeds of breathing through how we're going to continue to think about things, for the balance of this year. So thank you so much.
Johnson & Johnson at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers